AIDS Treatment News logo      

December 4, 2009

GSK warn US doctors of possible association between fosamprenavir and heart attack

"The move comes after a French study (FHDH ANRS CO4) presented to the Conference on Retroviruses and Opportunistic Infections earlier this year showed that each year of therapy with the drug increased the risk of heart attack by 54%.

"GSK are also reminding healthcare professionals of the importance of monitoring cholesterol and triglycerides before and during treatment with fosamprenavir. The company also recommends that other risk factors for cardiovascular disease, such as high blood pressure, diabetes and smoking should also be evaluated."

Read more in Aidsmap, December 3, 2009.